Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > 02291 SCIENTECH > Detailed Quotes

02291 SCIENTECH

Watchlist
28.650
+0.500+1.78%
Closed  02/03 16:08 CCT
High
28.850
Open
28.050
Turnover
2.51M
Low
27.250
Pre Close
28.150
Volume
89.00K
Market Cap
9.93B
P/E(TTM)
206.12
52wk High
30.650
Shares
346.75M
P/E(Static)
138.41
52wk Low
26.100
Float Cap
9.93B
Bid/Ask %
-9.09%
Historical High
30.650
Shs Float
346.75M
Volume Ratio
1.22
Historical Low
26.100
Dividend TTM
--
Div Yield TTM
--
P/B
20.36
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.03%
Amplitude
5.68%
Avg Price
28.243
Lot Size
1000
Float Cap
9.93B
Bid/Ask %
-9.09%
Historical High
30.650
Shs Float
346.75M
Volume Ratio
1.22
Historical Low
26.100
Dividend TTM
--
P/B
20.36
Dividend LFY
--
Turnover Ratio
0.03%
Amplitude
5.68%
Avg Price
28.243
Lot Size
1000
Price Forecast

News

Comment

No More
Company Overview More
Established in 1994, we have been committed to the R&D, production and commercialization of interventional medical devices mainly for structural heart disease, and have a track record spanning more than 20 years. According to the Frost & Sullivan report, based on the market share of China's congenital heart disease blocker products market in 2021, we are a leading interventional medical device supplier for congenital heart disease (the main application area of structural heart disease) in China, with a broad portfolio of marketing and pipeline products. According to the same source*, we are the largest manufacturer of congenital heart disease blocker products and related surgical ancillary products in China. Based on revenue confirmed from sales in China in 2021, our market share is 38.0%. Our oval hole unoccluded occlusion products and left ventricular occlusion products target cardiogenic strokes and related symptoms (another major application area of structural heart disease), and are among the few commercialized products that can seize major market opportunities. According to the Frost & Sullivan report, we have also developed the most comprehensive portfolio of heart valve research products in China to tap the huge market potential for treating valvular diseases. This is the biggest application area for structural heart disease, and is currently generally undeveloped in China.
CEO: Juan Chen
Market: Hong Kong motherboard
Listing Date: 11/08/2022
Paper Trade More
Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist